Seer (SEER)
(Delayed Data from NSDQ)
$2.24 USD
+0.08 (3.70%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SEER 2.24 +0.08(3.70%)
Will SEER be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SEER based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SEER
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
SEER: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
Other News for SEER
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment
New Share Price & Shareholder Rights Risk for Seer, Inc. – What’s the Latest?
Seer assumed with an Equal Weight at Morgan Stanley
Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript